Welcome to our dedicated page for Privia Health Group news (Ticker: PRVA), a resource for investors and traders seeking the latest updates and insights on Privia Health Group stock.
Privia Health Group, Inc. (Nasdaq: PRVA) is a technology-driven physician enablement company that regularly issues detailed updates on its operations, value-based care performance, and network expansion. Its news flow often includes quarterly financial results, guidance updates, and announcements related to Accountable Care Organizations (ACOs) and partnerships with independent physician groups.
Investors following PRVA news can expect recurring earnings releases that highlight metrics such as total revenue, gross profit, operating income, net income, Adjusted EBITDA, Implemented Providers, Value-Based Care Attributed Lives, Practice Collections, Care Margin, and Platform Contribution. The company frequently discusses its performance in the Medicare Shared Savings Program (MSSP) and other value-based arrangements, including aggregate shared savings achieved by its Privia Quality Network ACOs.
Privia Health also uses news releases to announce strategic transactions and geographic expansion. Recent examples include a definitive agreement to acquire an ACO business from Evolent Health, Inc., which serves more than 120,000 attributed lives, and entry into the Arizona market through a partnership with Integrated Medical Services, Inc., a large independent multi-specialty practice. These updates provide insight into how the company is growing its presence across 15 states and the District of Columbia and increasing the number of attributed lives in value-based care arrangements.
In addition, PRVA news may cover governance and board changes, such as the appointment of new directors with technology and cybersecurity expertise. For readers interested in physician enablement, value-based care, and healthcare technology, the Privia Health news feed offers a view into how the company reports its progress, adjusts its full-year guidance, and describes the performance of its physician networks and ACOs over time.
Privia Health (Nasdaq: PRVA) earned the 2026 HFMA MAP Award for High Performance in Revenue Cycle, marking recognition in nine of the last ten years. The award reflects sustained excellence across MAP Keys® metrics such as net collection rate, AR performance, denial prevention, and cost to collect.
Privia’s multi-year transformation—analytics, AI automation, provider engagement, and scalable operating models—drove strong MAP benchmark results and the national award presented March 18 at the HFMA Revenue Cycle Conference.
Privia Health (NASDAQ:PRVA), Amalgam Rx, and Exact Sciences (NASDAQ:EXAS) report a Privia-led colorectal cancer screening program that reached an 84% screening rate in 2024, above the 80% national goal. The EHR-integrated, automated outreach program engaged >42,000 patients (scaled to >100,000), processed ~23,000 orders within 48 hours, and found a 10% positivity rate identifying >550 patients needing follow-up.
The program used Cologuard as a noninvasive first-line option and embedded ordering, results, and follow-up into athenaClinicals to support value-based care and eCQM readiness.
Privia Health (Nasdaq: PRVA) reported full-year 2025 results with all operating and financial metrics at or above the high end of guidance. Total revenue was $2,122.8M (+22.3%), Adjusted EBITDA $125.5M (+38.8%), and net income $22.9M (+59.3%).
Year-end cash was $479.7M with no debt; 2025 operating cash flow was $163.4M (+49.5%). 2026 guidance targets ~20% Adjusted EBITDA growth at midpoint and expects ~80% conversion of Adjusted EBITDA to free cash flow.
Privia Health (Nasdaq: PRVA) expects to release financial results for the fourth quarter and full year ended December 31, 2025 before market open on Thursday, February 26, 2026. The release is expected to be publicly available by 7:00 AM ET and on the company's investor relations website. Management will host a conference call and live webcast to discuss results and outlook beginning at 8:00 AM ET the same day; the webcast will be archived for on-demand replay. To join the live call, dial 888-596-4144 (or 646-968-2525 internationally) and use Conference ID 5704885.
Privia Health (Nasdaq: PRVA) reported strong Q3 2025 results on November 6, 2025: total revenue $580.4M (+32.5% YoY), net income $6.9M (+94.1% YoY) and Adjusted EBITDA $38.2M (+61.6% YoY). Practice Collections rose to $940.4M (+27.1%) and Implemented Providers reached 5,250 (+13.1%).
The company signed a definitive agreement to acquire an ACO business from Evolent for $100M cash plus up to $13M earnout, expected to close in Q4 2025 and expand VBC attributed lives above 1.5M. Cash was $441.4M and no debt at 9/30/25; pro forma cash expected ≈$409.9M after pro forma items. FY'25 guidance was raised above prior high end across key metrics.
Privia Health (Nasdaq: PRVA) said it will report third-quarter and nine-month 2025 financial results before market open on Thursday, November 6, 2025. The press release is expected to be publicly available by 7:00 AM ET on the company's Investor Relations site at ir.priviahealth.com. Management will host a conference call and live webcast at 8:00 AM ET on November 6, 2025 to discuss results and outlook; the webcast will be archived for on-demand replay. Dial-in details for the live call are 888-596-4144 (US) or 646-968-2525 (international) with Conference ID 5704885.
Privia Health (Nasdaq: PRVA) has announced a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health (NYSE: EVH) for $100 million in cash, with an additional performance-based payment of up to $13 million.
The acquisition will add over 120,000 attributed lives through Medicare Shared Savings Program (MSSP), commercial, and Medicare Advantage programs, bringing Privia's total attributed lives in value-based care arrangements to 1.5 million across multiple programs. The deal, expected to close in Q4 2025, will be financed with cash on hand and is projected to contribute positively to Adjusted EBITDA in 2026.
Evolent Health (NYSE: EVH) has announced the sale of its value-based primary care business, Evolent Care Partners (ECP), to Privia Health Group for up to $113 million in cash. The transaction includes $100 million at closing and additional payments in Fall 2026 based on MSSP performance.
The strategic divestiture involves ECP's operations serving over 120,000 members through partnerships with 1,000+ physicians in the Medicare Shared Savings Program. The company plans to use proceeds to prepay senior term debt, expecting to improve annual cash flow by over $7 million.
Evolent reaffirmed its Q3 2025 guidance with revenue of $460-480 million and Adjusted EBITDA of $34-42 million, as well as full-year 2025 outlook of $1.85-1.88 billion in revenue and $140-165 million in Adjusted EBITDA, before accounting for the transaction impact.
Privia Health (Nasdaq: PRVA) has announced exceptional performance in the 2024 Medicare Shared Savings Program, achieving $233.1 million in shared savings, marking a significant 32% increase from 2023. The company's nine Accountable Care Organizations managed $2.5 billion in healthcare benchmark spend through approximately 3,280 providers, serving 194,700 Medicare beneficiaries.
The company's Mid-Atlantic ACO achieved the highest savings rate (10.6%) among ACOs with over 40,000 attributed lives. Notable achievements include beneficiary expenditures 8% lower than median ACO and an impressive aggregate quality score of 89%. Following these strong results, Privia Health has increased its 2025 Adjusted EBITDA guidance to $113-116 million.
Privia Health (Nasdaq: PRVA) reported strong Q2 2025 financial results, with significant growth across key metrics. Total revenue increased 23.4% to $521.2 million, while Practice Collections grew 18.5% to $862.9 million. The company achieved Adjusted EBITDA of $29.0 million, up 31.6% year-over-year.
Notable operational highlights include a 13.8% increase in Implemented Providers to 5,125 and a 15.2% growth in Value-Based Care Attributed Lives to 1.38 million. Following the IMS transaction in Arizona, Privia maintains a strong balance sheet with $390.1 million in cash and no debt.
Based on strong performance, Privia raised its FY2025 guidance above the high end of previous ranges for Practice Collections, GAAP Revenue, Platform Contribution, and Adjusted EBITDA.